XOMA Royalty (NASDAQ:XOMA) Upgraded at Wall Street Zen

Key Points

• XOMA Royalty was upgraded from a "hold" to a "buy" rating by Wall Street Zen, with additional supportive ratings from Benchmark and HC Wainwright.
• Shares of XOMA Royalty are currently trading at $26.50, representing a 12-month high of $35.00 and a market cap of $317.21 million.
• Insider activity indicates significant share sales, with major shareholder Bvf Partners L. P/Il selling 392,723 shares and CEO Owen Hughes selling 25,637 shares, leading to a notable decrease in their holdings.

Wall Street Zen upgraded shares of XOMA Royalty (NASDAQ:XOMA - Free Report) from a hold rating to a buy rating in a research report released on Monday morning.

A number of other brokerages have also recently issued reports on XOMA. HC Wainwright restated a "buy" rating and set a $104.00 target price on shares of XOMA Royalty in a research report on Wednesday, May 28th. Benchmark started coverage on shares of XOMA Royalty in a research report on Thursday, April 17th. They set a "buy" rating and a $35.00 target price for the company.

XOMA Royalty Stock Up 4.3%

XOMA Royalty stock traded up $1.32 during mid-day trading on Monday, reaching $32.21. 40,164 shares of the company's stock were exchanged, compared to its average volume of 43,073. The company has a market cap of $385.40 million, a P/E ratio of -28.00 and a beta of 1.00. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $35.00. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The company has a fifty day moving average of $26.15 and a 200-day moving average of $24.28.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. The company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $9.39 million. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. Sell-side analysts expect that XOMA Royalty will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In other news, CEO Owen Hughes sold 25,637 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the transaction, the chief executive officer directly owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. The trade was a 29.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider directly owned 1,267,545 shares in the company, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.10% of the stock is owned by insiders.

Institutional Trading of XOMA Royalty

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its holdings in shares of XOMA Royalty by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,585 shares during the period. JPMorgan Chase & Co. boosted its position in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 543 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 1,183 shares in the last quarter. Deutsche Bank AG boosted its position in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 6,309 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of XOMA Royalty by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.